---
title: "Genmab’s Promising Future: Buy Rating Backed by Strong R&D and Market Performance"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/269438892.md"
description: "William Blair analyst Matt Phipps reiterated a Buy rating on Genmab (GMAB) stock due to strong R&D progress and market performance. Positive results from the EPCORE FL-1 study of Epkinly and upcoming catalysts in ovarian cancer and DLBCL support the rating. Guggenheim also reiterated a Buy rating with a $45.00 price target."
datetime: "2025-12-11T22:25:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/269438892.md)
  - [en](https://longbridge.com/en/news/269438892.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/269438892.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/269438892.md) | [English](https://longbridge.com/en/news/269438892.md)


# Genmab’s Promising Future: Buy Rating Backed by Strong R&D and Market Performance

William Blair analyst Matt Phipps has reiterated their bullish stance on GMAB stock, giving a Buy rating on December 8.

### Claim 50% Off TipRanks Premium and Invest with Confidence

-   Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

Matt Phipps has given his Buy rating due to a combination of factors that highlight Genmab’s promising future prospects. The company has demonstrated significant progress in its R&D pipeline, particularly with the positive results from the EPCORE FL-1 study of Epkinly, which has shown impressive progression-free survival and overall survival rates. This reinforces confidence in Epkinly’s potential and supports its recent approval.  
Moreover, Genmab’s stock has shown substantial growth, outperforming the broader market, and there are several upcoming catalysts that could further enhance its value. These include pivotal readouts for Rina-S in ovarian cancer and Epkinly in frontline DLBCL, as well as potential advancements in head and neck cancer treatments. The late-stage pipeline is expected to drive long-term revenue growth, justifying the Outperform rating and the Buy recommendation.

In another report released on December 8, Guggenheim also reiterated a Buy rating on the stock with a $45.00 price target.

### 相關股票

- [Genmab A/S (GMAB.US)](https://longbridge.com/zh-HK/quote/GMAB.US.md)

## 相關資訊與研究

- [Genmab Discloses Orbis as New 5% Major Shareholder](https://longbridge.com/zh-HK/news/281419643.md)
- [Genmab Updates Articles of Association, Expands Capital Issuance Flexibility](https://longbridge.com/zh-HK/news/280180559.md)
- [Genmab (CPSE:GMAB) Valuation Check As Amlenetug Clinical Progress Draws Fresh Investor Attention](https://longbridge.com/zh-HK/news/280355648.md)
- [Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons](https://longbridge.com/zh-HK/news/281415009.md)
- [Genmab Reshapes Board Leadership and Approves New Employee Equity Grants After 2026 AGM](https://longbridge.com/zh-HK/news/279836542.md)